Beyond the Competition: Insights from Returning CACHE Participants
Open science competitions, such as Conscience’s CACHE Challenges, provide multiple benefits for early-stage drug discovery and the companies and researchers that participate in them. While hit-finding is the ultimate goal, the impact of participating in a challenge goes far beyond the competition itself. The challenges offer an opportunity to share data across organizations, accelerate discovery, […]
Second call for applications for expanded DMOS program includes clinical research
We’re pleased to announce that applications are now open for the second round of our Developing Medicines through Open Science (DMOS) program and that the program has expanded to support clinical-stage projects alongside preclinical research. This expansion reflects our commitment to moving promising therapies closer to patients while continuing to apply open science principles that […]
Open Science as a Catalyst for Canada’s Innovation Strategy
Innovation depends on the ability to share and build on ideas, yet too much scientific knowledge remains siloed. In this op-ed for the Canadian Science Policy Centre, Conscience’s Richard Gold and Estrid Jakobsen argue that open science should be a central pillar of Canada’s innovation strategy, particularly in an era shaped by AI, health challenges, […]
Agora Open Science Trust selects lead development candidate for pediatric brain cancer therapy
We’re pleased to share a joint press release with the Agora Open Science Trust announcing the nomination of M4K2009 as the lead development candidate in their open science program for DIPG, a rare and devastating pediatric brain cancer. This milestone reflects the strength of collaborative, open science-driven research and highlights the meaningful progress supported through […]
Conscience and Every Cure launch partnership to advance drug repurposing
We are pleased to announce a new partnership with Every Cure. Every Cure is a U.S.-based nonprofit on a mission to save and improve lives by repurposing drugs; the organization leverages AI to uncover new uses for existing medicines to address diseases with high unmet need. They validate the most promising opportunities through laboratory research […]
Intellectual Property Strategies in the age of AI
In this recently published op-ed in CanadianSME, Conscience’s Chief Policy and Partnerships Officer, Richard Gold, and CEO, Peng Fu, call for biopharma SMEs to rethink their reliance on patents as they adopt AI. They argue that traditional patent-first IP strategies are increasingly misaligned with how AI actually works, because machine learning depends on broad data […]
From risk to resilience: rethinking innovation in drug discovery
In a new op-ed for Drug Discovery World, Conscience CEO Peng Fu and Communications Lead Estrid Jakobsen argue that the biggest opportunities for progress in drug discovery lie not only in new technologies, but in reimagining how science itself is organized. They explore how open science, creative collaboration, and alternative incentive models can help the […]
Enamine joins the CACHE Governing Board
We are pleased to announce that Enamine has joined the CACHE (Critical Assessment of Computational Hit-finding Experiments) Governing Board. Enamine has already played a central role in CACHE, serving as the primary supplier of compounds for the challenges since the very beginning. Founded in 1991, Enamine is the leading provider of chemical compounds and a […]
CACHE Challenge #4 identifies a novel ‘hit’ for a cancer immunotherapy target
In our fourth CACHE Challenge, researchers from across the globe used computational methods to predict molecules to bind CBLB, a cancer immunotherapy target. The top-performing team identified a molecule that was not only bioactive but also chemically novel—an especially significant achievement given the existing patent coverage around this target and the difficulty pharmaceutical companies have […]
Peng Fu Appointed CEO of Conscience
We’re excited to announce that Peng Fu has joined Conscience as our new Chief Executive Officer. He brings deep experience in biotech, finance, and law, and we’re looking forward to seeing how his leadership can help us move closer to our vision: a future where no patient is left behind. For more information, contact:Estrid Jakobsen […]
Canadian SMEs Should Shift Perspectives on Patents to Enable Growth
In a recent op-ed published by Canadian SME Magazine, Conscience’s Chief Policy and Partnerships Officer Richard Gold makes the case for why Canadian science-based SMEs should consider open science not just as a philosophy—but as a practical strategy for growth. In an era where funding is uncertain and the costs of pursuing patents are often […]
Conscience sparks dialogue on open science at the Fonds de solidarité FTQ Life Sciences Symposium
A few weeks ago, Conscience’s Chief Science Officer Aled Edwards and board member Florence Rozen—who also serves as Scientific Director of Investments at the Fonds de solidarité FTQ—participated in a standout panel on open science at the Fonds’ invitation-only Life Sciences Symposium in Montréal. The event marked the Fonds’ 35-year commitment to innovation in Québec’s […]
